Sarcopenia Is Associated With a Risk of Mortality in People With Type 2 Diabetes Mellitus.

Aged Aged, 80 and over Cohort Studies Diabetes Mellitus, Type 2 / diagnosis Female Follow-Up Studies Hand Strength / physiology Humans Male Mortality / trends Muscle Strength / physiology Prospective Studies Risk Factors Sarcopenia / diagnosis
aged diabetes mortality muscle mass older sarcopenia

Journal

Frontiers in endocrinology
ISSN: 1664-2392
Titre abrégé: Front Endocrinol (Lausanne)
Pays: Switzerland
ID NLM: 101555782

Informations de publication

Date de publication:
2021
Historique:
received: 26 09 2021
accepted: 25 10 2021
entrez: 3 12 2021
pubmed: 4 12 2021
medline: 19 2 2022
Statut: epublish

Résumé

Sarcopenia has reportedly been associated with increased risk of mortality in general populations. However, few studies have investigated the association between sarcopenia and mortality in older people with type 2 diabetes mellitus (T2D). This study aimed to investigate the effect of sarcopenia on incident all-cause mortality in older people with T2D. Low muscle strength were set at handgrip strength <28 kg for men and <18 kg for women, and low skeletal muscle mass index (SMI), evaluated using the impedance body composition analyzer, were set at SMI <7.0 kg/m In this prospective cohort study, 396 people with an average age and duration of diabetes of 71.3 (6.3) years and 16.3 (11.3) years, respectively, were included. Of those included, 14.6% had sarcopenia. During the average 40.5 (16.5) months of follow-up, 13 people (6 out of the 338 without sarcopenia and 7 out of the 58 with sarcopenia) died. Incident rate were 5.1/1000 person years of follow-up in people without sarcopenia and 41.3/1000 person years of follow-up in people with sarcopenia. According to Cox regression analysis, sarcopenia was associated with all-cause mortality (adjusted hazard ratio: 6.12, 95% confidence interval: 1.52-24.7, Sarcopenia is associated with incident all-cause mortality in older outpatients with T2D.

Sections du résumé

Background
Sarcopenia has reportedly been associated with increased risk of mortality in general populations. However, few studies have investigated the association between sarcopenia and mortality in older people with type 2 diabetes mellitus (T2D). This study aimed to investigate the effect of sarcopenia on incident all-cause mortality in older people with T2D.
Methods
Low muscle strength were set at handgrip strength <28 kg for men and <18 kg for women, and low skeletal muscle mass index (SMI), evaluated using the impedance body composition analyzer, were set at SMI <7.0 kg/m
Results
In this prospective cohort study, 396 people with an average age and duration of diabetes of 71.3 (6.3) years and 16.3 (11.3) years, respectively, were included. Of those included, 14.6% had sarcopenia. During the average 40.5 (16.5) months of follow-up, 13 people (6 out of the 338 without sarcopenia and 7 out of the 58 with sarcopenia) died. Incident rate were 5.1/1000 person years of follow-up in people without sarcopenia and 41.3/1000 person years of follow-up in people with sarcopenia. According to Cox regression analysis, sarcopenia was associated with all-cause mortality (adjusted hazard ratio: 6.12, 95% confidence interval: 1.52-24.7,
Conclusion
Sarcopenia is associated with incident all-cause mortality in older outpatients with T2D.

Identifiants

DOI: 10.3389/fendo.2021.783363 PMID: 34858351 PMC: PMC8632440
pubmed: 34858351
doi: 10.3389/fendo.2021.783363
pmc: PMC8632440
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

783363

Informations de copyright

Copyright © 2021 Takahashi, Hashimoto, Kaji, Sakai, Okamura, Kitagawa, Okada, Nakanishi, Majima, Senmaru, Ushigome, Hamaguchi, Asano, Yamazaki and Fukui.

Déclaration de conflit d'intérêts

YH reports personal fees from Novo Nordisk Pharma Ltd., Daiichi Sankyo Co. Ltd., Sanofi K.K., Mitsubishi Tanabe Pharma Corp., Ono Pharma Co., Ltd., Takeda Pharma Co., Ltd., and Sumitomo Dainippon Pharma Co. Ltd. EU received personal fees from MSD K.K., Mitsubishi Tanabe Pharma Corp., AstraZeneca plc, Daiichi Sankyo Co. Ltd., Novo Nordisk Pharma Ltd., Taisho Toyama Pharma Co., Ltd., Kowa Pharma Co. Ltd., Takeda Pharma Co., Ltd., Kyowa Kirin Co. Ltd., Sumitomo Dainippon Pharma Co. Ltd., Astellas Pharma Inc., and Nippon Boehringer Ingelheim Co. Ltd. outside the submitted work and received grant support from the Astellas Foundation for Research on Metabolic Disorders and the Japanese Study Group for Physiology and Management of Blood Pressure, donated fund Laboratory of Diabetes therapeutics is an endowment department, supported with an unrestricted grant from Ono Pharma. Co., Ltd. MH received grants from Daiichi Sankyo Co. Ltd., Astellas Pharma Inc., Mitsubishi Tanabe Pharma Corp., Novo Nordisk Pharma Ltd., Nippon Boehringer Ingelheim Co. Ltd., Sanofi K.K., Takeda Pharma Co. Ltd, Sumitomo Dainippon Pharma Co. Ltd., Asahi Kasei Pharma, Kyowa Kirin Co. Ltd., and Eli Lilly Japan K.K., outside the submitted work. MA received personal fees from Takeda Pharmaceutical Co., Ltd., Abbott Japan Co., Ltd., Sumitomo Dainippon Pharma Co., Ltd., Kowa Pharmaceutical Co., Ltd., Novo Nordisk Pharma Ltd., Ono Pharmaceutical Co., Ltd., AstraZeneca K.K., and Chugai Pharmaceutical Co., Ltd., outside the submitted work. MY received personal fees from Ono Phama Co., Ltd., Kowa Pharma Co. Ltd., AstraZeneca plc., Sumitomo Dainippon Pharma Co. Ltd., Kyowa Kirin Co. Ltd., MSD K.K., Takeda Pharma Co. Ltd, Kowa Pharma Co. Ltd., and Daiichi Sankyo Co. Ltd. outside the submitted work. MF received grants from Taisho Pharma Co., Ltd., Mitsubishi Tanabe Pharma Corp, Novo Nordisk Pharma Ltd., Ono Pharma Co. Ltd., Kowa Pharma Co. Ltd., Sanofi K.K., Nippon Boehringer Ingelheim Co. Ltd., Daiichi Sankyo Co. Ltd., Kissei Phama Co. Ltd., MSD K.K., Kyowa Kirin Co., Ltd., Sumitomo Dainippon Pharma Co., Ltd., Eli Lilly Japan K.K., Tejin Pharma Ltd., Takeda Pharma Co. Ltd., Nippon Chemiphar Co., Ltd., Astellas Pharma Inc., Abbott Japan Co. Ltd., Sanwa Kagagu Kenkyusho CO., LtD., Johnson & Johnson k.k. Medical Co., and Terumo Corp., and received honoraria from AstraZeneca K.K., Taisho Pharma Co., Ltd., Ono Pharma Co. Ltd., Novo Nordisk Pharma Ltd., Sanofi K.K., Teijin Pharma Ltd., Takeda Pharma Co. Ltd., Astellas Pharma Inc., MSD K.K., Mitsubishi Tanabe Pharma Corp., Eli Lilly Japan K.K., Kissei Pharma Co., Ltd., Sumitomo Dainippon Pharma Co. Ltd., Daiichi Sankyo Co. Ltd., Mochida Pharma Co. Ltd., Kowa Pharma Co. Ltd., Arkray Inc., Abbott Japan Co. Ltd., Sanwa Kagaku Kenkyusho Co. Ltd., Kyowa Kirin Co. Ltd., Nippon Boehringer Ingelheim Co., Ltd., Medtronic Japan Co. Ltd., Bayer Yakuhin, Ltd., and Nipro Corp. outside the submitted work. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Références

J Am Med Dir Assoc. 2021 Apr;22(4):816-820.e2
pubmed: 33453174
J Cachexia Sarcopenia Muscle. 2017 Apr;8(2):238-244
pubmed: 27897430
Nutrients. 2021 Jul 08;13(7):
pubmed: 34371843
Nutrients. 2021 Jan 09;13(1):
pubmed: 33435310
PLoS One. 2017 Jan 17;12(1):e0169548
pubmed: 28095426
J Geriatr Med Gerontol. 2016;2(2):
pubmed: 31692858
J Am Med Dir Assoc. 2021 Apr;22(4):834-838.e1
pubmed: 33278348
BMC Geriatr. 2019 Nov 20;19(1):318
pubmed: 31747923
Endocr J. 2018 Apr 26;65(4):395-402
pubmed: 29375081
Int J Colorectal Dis. 2021 Jun;36(6):1077-1096
pubmed: 33481108
J Am Med Dir Assoc. 2020 Mar;21(3):300-307.e2
pubmed: 32033882
Sci Rep. 2017 Aug 1;7(1):7041
pubmed: 28765572
Biofactors. 2009 Jan-Feb;35(1):28-35
pubmed: 19319843
Diabetes Care. 2016 Jan;39 Suppl 1:S13-22
pubmed: 26696675
J Diabetes. 2016 Sep;8(5):736-7
pubmed: 27038414
J Am Med Dir Assoc. 2015 Feb;16(2):173.e17-22
pubmed: 25499428
Geriatr Gerontol Int. 2015 Aug;15(8):1013-22
pubmed: 25345548
Geriatr Gerontol Int. 2019 Feb;19(2):153-158
pubmed: 30585390
BMJ Open. 2018 Nov 12;8(11):e021252
pubmed: 30420343
Chron Respir Dis. 2017 Feb;14(1):85-99
pubmed: 27923981
J Cachexia Sarcopenia Muscle. 2019 Aug;10(4):903-918
pubmed: 31020810
Adv Exp Med Biol. 2017;987:213-218
pubmed: 28971460
Circ J. 2016 Jun 24;80(7):1537-8
pubmed: 27264417
Geriatr Gerontol Int. 2018 Sep;18(9):1345-1349
pubmed: 30039599
Calcif Tissue Int. 2018 Mar;102(3):287-295
pubmed: 29101476
Nutrients. 2020 Oct 21;12(10):
pubmed: 33096793
Bone Marrow Transplant. 2013 Mar;48(3):452-8
pubmed: 23208313
Clin Nutr. 2021 Apr;40(4):1613-1620
pubmed: 33752149
Ther Adv Endocrinol Metab. 2019 Apr 22;10:2042018819842971
pubmed: 31040938
J Clin Med. 2019 May 19;8(5):
pubmed: 31109123
Am J Cardiol. 2017 Apr 15;119(8):1275-1280
pubmed: 28215411
Maturitas. 2017 Sep;103:16-22
pubmed: 28778327
J Clin Biochem Nutr. 2019 Jul;65(1):23-28
pubmed: 31379410
J Diabetes Metab Disord. 2017 May 16;16:21
pubmed: 28523252
Am J Clin Nutr. 2017 Apr;105(4):913-927
pubmed: 28228420
Calcif Tissue Int. 2020 Nov;107(5):453-463
pubmed: 32772138
Age Ageing. 2019 May 1;48(3):413-418
pubmed: 30608508
BMC Nephrol. 2020 May 6;21(1):166
pubmed: 32375664
J Clin Endocrinol Metab. 2003 Dec;88(12):5766-72
pubmed: 14671166
J Diabetes. 2019 Jun;11(6):477-483
pubmed: 30407749
Am J Kidney Dis. 2009 Jun;53(6):982-92
pubmed: 19339088
Metabolism. 2020 Feb;103:154044
pubmed: 31812628
J Cachexia Sarcopenia Muscle. 2016 Jun;7(3):290-8
pubmed: 27239410
Nutrients. 2020 Nov 01;12(11):
pubmed: 33139628
BMJ Open Diabetes Res Care. 2020 Feb;8(1):
pubmed: 32098897
Am J Physiol Regul Integr Comp Physiol. 2015 Apr 1;308(7):R597-604
pubmed: 25589014
Maturitas. 2021 Mar;145:38-48
pubmed: 33541561

Auteurs

Fuyuko Takahashi (F)

Department of Endocrinology and Metabolism, Kyoto Prefectural University of Medicine, Graduate School of Medical Science, Kyoto, Japan.

Yoshitaka Hashimoto (Y)

Department of Endocrinology and Metabolism, Kyoto Prefectural University of Medicine, Graduate School of Medical Science, Kyoto, Japan.

Ayumi Kaji (A)

Department of Endocrinology and Metabolism, Kyoto Prefectural University of Medicine, Graduate School of Medical Science, Kyoto, Japan.

Ryosuke Sakai (R)

Department of Endocrinology and Metabolism, Kyoto Prefectural University of Medicine, Graduate School of Medical Science, Kyoto, Japan.

Takuro Okamura (T)

Department of Endocrinology and Metabolism, Kyoto Prefectural University of Medicine, Graduate School of Medical Science, Kyoto, Japan.

Noriyuki Kitagawa (N)

Department of Endocrinology and Metabolism, Kyoto Prefectural University of Medicine, Graduate School of Medical Science, Kyoto, Japan.
Department of Diabetology, Kameoka Municipal Hospital, Kameoka, Japan.

Hiroshi Okada (H)

Department of Endocrinology and Metabolism, Kyoto Prefectural University of Medicine, Graduate School of Medical Science, Kyoto, Japan.
Department of Diabetes and Endocrinology, Matsushita Memorial Hospital, Moriguchi, Japan.

Naoko Nakanishi (N)

Department of Endocrinology and Metabolism, Kyoto Prefectural University of Medicine, Graduate School of Medical Science, Kyoto, Japan.

Saori Majima (S)

Department of Endocrinology and Metabolism, Kyoto Prefectural University of Medicine, Graduate School of Medical Science, Kyoto, Japan.

Takafumi Senmaru (T)

Department of Endocrinology and Metabolism, Kyoto Prefectural University of Medicine, Graduate School of Medical Science, Kyoto, Japan.

Emi Ushigome (E)

Department of Endocrinology and Metabolism, Kyoto Prefectural University of Medicine, Graduate School of Medical Science, Kyoto, Japan.

Masahide Hamaguchi (M)

Department of Endocrinology and Metabolism, Kyoto Prefectural University of Medicine, Graduate School of Medical Science, Kyoto, Japan.

Mai Asano (M)

Department of Endocrinology and Metabolism, Kyoto Prefectural University of Medicine, Graduate School of Medical Science, Kyoto, Japan.

Masahiro Yamazaki (M)

Department of Endocrinology and Metabolism, Kyoto Prefectural University of Medicine, Graduate School of Medical Science, Kyoto, Japan.

Michiaki Fukui (M)

Department of Endocrinology and Metabolism, Kyoto Prefectural University of Medicine, Graduate School of Medical Science, Kyoto, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Personnes › Tranches d'âge › Adulte › Sujet âgé › Sarcopenia Is Associated With a Risk of...
questionsmedicales.fr › Personnes › Tranches d'âge › Adulte › Sujet âgé › Sujet âgé de 80 ans ou plus › Sarcopenia Is Associated With a Risk of...
questionsmedicales.fr › Environnement et santé publique › Santé publique › Méthodes épidémiologiques › Caractéristiques des études épidémiologiques › Études épidémiologiques › Études de cohortes › Sarcopenia Is Associated With a Risk of...
questionsmedicales.fr › Maladies endocriniennes › Diabète › Diabète de type 2 › Sarcopenia Is Associated With a Risk of...
questionsmedicales.fr › Environnement et santé publique › Santé publique › Méthodes épidémiologiques › Caractéristiques des études épidémiologiques › Études épidémiologiques › Études de cohortes › Études de suivi › Sarcopenia Is Associated With a Risk of...
questionsmedicales.fr › Phénomènes physiologiques de l'appareil locomoteur et du système nerveux › Phénomènes physiologiques du système locomoteur › Force musculaire › Force de la main › Sarcopenia Is Associated With a Risk of...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Sarcopenia Is Associated With a Risk of...
questionsmedicales.fr › Environnement et santé publique › Santé publique › Méthodes épidémiologiques › Collecte de données › Registre civil › Mortalité › Sarcopenia Is Associated With a Risk of...
questionsmedicales.fr › Phénomènes physiologiques de l'appareil locomoteur et du système nerveux › Phénomènes physiologiques du système locomoteur › Force musculaire › Sarcopenia Is Associated With a Risk of...
questionsmedicales.fr › Environnement et santé publique › Santé publique › Méthodes épidémiologiques › Caractéristiques des études épidémiologiques › Études épidémiologiques › Études de cohortes › Études prospectives › Sarcopenia Is Associated With a Risk of...
questionsmedicales.fr › Environnement et santé publique › Santé publique › Méthodes épidémiologiques › Statistiques comme sujet › Probabilité › Risque › Facteurs de risque › Sarcopenia Is Associated With a Risk of...
questionsmedicales.fr › États, signes et symptômes pathologiques › Signes et symptômes › Manifestations neurologiques › Manifestations neuromusculaires › Amyotrophie › Sarcopénie › Sarcopenia Is Associated With a Risk of...